[go: up one dir, main page]

PL355663A1 - Farmaceutyczne kombinacje oraz ich zastosowanie wleczeniu zaburzeń żołądkowo-jelitowych - Google Patents

Farmaceutyczne kombinacje oraz ich zastosowanie wleczeniu zaburzeń żołądkowo-jelitowych

Info

Publication number
PL355663A1
PL355663A1 PL00355663A PL35566300A PL355663A1 PL 355663 A1 PL355663 A1 PL 355663A1 PL 00355663 A PL00355663 A PL 00355663A PL 35566300 A PL35566300 A PL 35566300A PL 355663 A1 PL355663 A1 PL 355663A1
Authority
PL
Poland
Prior art keywords
gastrointestinal disorders
pharmaceutical combinations
treating gastrointestinal
combination
agent
Prior art date
Application number
PL00355663A
Other languages
English (en)
Other versions
PL202201B1 (pl
Inventor
Stephan Anthony Billstein
Peter Dumovic
Nicola Franco
Mark Thomas Iwicki
Hans-Jurgen Pfannkuche
Edward Joseph Wilusz Jr.
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL355663A1 publication Critical patent/PL355663A1/pl
Publication of PL202201B1 publication Critical patent/PL202201B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL355663A 1999-12-10 2000-12-08 Kombinacja farmaceutyczna, jej zastosowanie oraz kompozycja farmaceutyczna zawierająca taką kombinację farmaceutyczną PL202201B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10
PCT/EP2000/012420 WO2001041748A2 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders

Publications (2)

Publication Number Publication Date
PL355663A1 true PL355663A1 (pl) 2004-05-04
PL202201B1 PL202201B1 (pl) 2009-06-30

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
PL355663A PL202201B1 (pl) 1999-12-10 2000-12-08 Kombinacja farmaceutyczna, jej zastosowanie oraz kompozycja farmaceutyczna zawierająca taką kombinację farmaceutyczną

Country Status (30)

Country Link
EP (3) EP1286668B1 (pl)
JP (1) JP2003523324A (pl)
KR (1) KR100765579B1 (pl)
CN (2) CN1875966A (pl)
AR (1) AR026916A1 (pl)
AT (1) ATE293971T1 (pl)
AU (2) AU778869B2 (pl)
BR (1) BR0016275A (pl)
CA (1) CA2388959A1 (pl)
CO (1) CO5261535A1 (pl)
CZ (1) CZ300690B6 (pl)
DE (1) DE60019814T2 (pl)
DK (1) DK1286668T3 (pl)
ES (1) ES2240229T3 (pl)
HU (1) HUP0301122A3 (pl)
IL (2) IL149496A0 (pl)
MX (1) MXPA02005695A (pl)
MY (1) MY133423A (pl)
NO (1) NO20022680L (pl)
NZ (2) NZ531489A (pl)
PE (1) PE20011030A1 (pl)
PL (1) PL202201B1 (pl)
PT (1) PT1286668E (pl)
RU (1) RU2264215C2 (pl)
SG (1) SG152025A1 (pl)
SK (1) SK8062002A3 (pl)
TR (1) TR200402293T2 (pl)
TW (1) TWI263496B (pl)
WO (1) WO2001041748A2 (pl)
ZA (1) ZA200204493B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284732A2 (en) * 2000-05-18 2003-02-26 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
KR20050094843A (ko) 2003-01-13 2005-09-28 다이노젠 파마세우티컬스, 인코포레이티드 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
RS20050868A (en) * 2003-05-27 2007-08-03 Altana Pharma Ag., Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
AU2005261778A1 (en) * 2004-07-14 2006-01-19 Novartis Ag Combination of DPP-IV inhibitors and compounds modulating 5-HT3 and/or 5-HT4 receptors
EP1853256A2 (en) * 2005-01-31 2007-11-14 Novartis AG Organic compounds
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP1987009A1 (en) 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
KR20090019914A (ko) * 2006-06-15 2009-02-25 노파르티스 아게 테가세로드를 단독으로 포함하거나 또는 양성자 펌프 억제제와 조합으로 포함하는, 위 손상의 치료 또는 예방용 조성물
WO2008130464A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
LT3354276T (lt) * 2007-11-13 2020-04-27 Meritage Pharma, Inc. Kompozicijos, skirtos skrandžio ir žarnyno uždegimo gydymui
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
EP0617620B1 (en) * 1991-12-21 1998-09-09 Smithkline Beecham Plc Use of 5-ht4 - antagonists for the manufacture of a medicament for the treatment of urinary incontinence
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
DE60019814D1 (de) 2005-06-02
IL149496A (en) 2009-12-24
WO2001041748A3 (en) 2002-12-19
MXPA02005695A (es) 2002-09-18
CN1875966A (zh) 2006-12-13
CN1409634A (zh) 2003-04-09
IL149496A0 (en) 2002-11-10
PT1286668E (pt) 2005-08-31
PE20011030A1 (es) 2001-10-31
NZ531489A (en) 2005-09-30
BR0016275A (pt) 2002-08-27
CZ20021967A3 (cs) 2002-08-14
SG152025A1 (en) 2009-05-29
MY133423A (en) 2007-11-30
RU2002118316A (ru) 2004-02-20
ES2240229T3 (es) 2005-10-16
AU2005200797B2 (en) 2008-01-24
DK1286668T3 (da) 2005-08-15
ZA200204493B (en) 2003-09-29
CN1310644C (zh) 2007-04-18
NZ566800A (en) 2009-11-27
NO20022680L (no) 2002-08-12
HUP0301122A3 (en) 2005-03-29
EP1286668B1 (en) 2005-04-27
KR20030016208A (ko) 2003-02-26
EP1913944A1 (en) 2008-04-23
ATE293971T1 (de) 2005-05-15
PL202201B1 (pl) 2009-06-30
SK8062002A3 (en) 2003-04-01
CZ300690B6 (cs) 2009-07-15
AU778869B2 (en) 2004-12-23
EP1286668A2 (en) 2003-03-05
HUP0301122A2 (hu) 2003-08-28
DE60019814T2 (de) 2006-03-02
TWI263496B (en) 2006-10-11
EP1488788A1 (en) 2004-12-22
AU2005200797A1 (en) 2005-03-17
NO20022680D0 (no) 2002-06-06
CA2388959A1 (en) 2001-06-14
WO2001041748A2 (en) 2001-06-14
KR100765579B1 (ko) 2007-10-09
RU2264215C2 (ru) 2005-11-20
JP2003523324A (ja) 2003-08-05
AR026916A1 (es) 2003-03-05
AU2672801A (en) 2001-06-18
TR200402293T2 (tr) 2004-10-21
CO5261535A1 (es) 2003-03-31

Similar Documents

Publication Publication Date Title
PL355663A1 (pl) Farmaceutyczne kombinacje oraz ich zastosowanie wleczeniu zaburzeń żołądkowo-jelitowych
CY2166B1 (en) Freeze-dried composition containing ondansetron
HUP0001089A2 (hu) Gyógyászati készítmények férfiak erekciós zavarainak kezelésére
GB2295317B (en) Liquid composition containing ondansetron
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
BR0212778A (pt) Composições de desintegração intra-oral organolepticamente aceitáveis
RU2002105377A (ru) Ксенон-антагонист nmda
WO2007071394A3 (en) Combination of a 5-ht4 agonist with a cholinesterase inhibitor
MY129314A (en) Pharmaceutical composition comprising sumatriptan
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
WO2004096118A3 (en) Composition for improving cognition and memory
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods
ECSP003820A (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
HUP0303754A3 (en) Use of radical scavenging compounds for preparation of pharmaceutical compsoition suitable for treatment and prevention of no-dependent microcirculation disorders
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine
MY138979A (en) The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20101208